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Abstract  7 
For regulatory information requirements, developmental toxicity testing is often conducted in 8 
two mammalian species. In order to provide a set of reference compounds that could be 9 
used to explore alternative approaches to supersede testing in a second species, a 10 
retrospective data analysis was conducted. The aim was to identify compounds for which 11 
species sensitivity differences between rats and rabbits are not caused by maternal toxicity 12 
or toxicokinetic differences. A total of 330 compounds were analysed and classified 13 
according to their species-specific differences. A lack of concordance between rat and rabbit 14 
was observed in 24% of the compounds, of which 10% were found to be selective 15 
developmental toxicants in one of the species. In contrast to previously published analyses 16 
the presented comparison is based entirely on publically data allowing validating and 17 
comparing alternative approaches for developmental toxicity testing. Furthermore, this list 18 
could be useful to identify mechanisms leading to species differences. 19 
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1. Introduction 25 
The assessment of potential developmental toxicity is an integral part of international 26 
regulations for the risk assessment of pharmaceuticals, industrial chemicals, food additives, 27 
biocides and plant protection products [1–3]. At present, such an assessment is typically 28 
conducted based on OECD or ICH (for pharmaceuticals) guidelines. These guidelines are 29 
primarily using mammalian models, which are laborious, time-consuming and involve the 30 
use of animal test. Since the thalidomide tragedy, developmental toxicity studies are often 31 
required to be conducted in two mammalian species, in a rodent and a non-rodent species 32 
[3]. Therefore, typically rats and rabbits are used as models for developmental toxicity 33 
testing. There have been discussions on the principal requirement for mammalian test, for 34 
ethical reasons and also with regards to the reliability of extrapolations to humans [4]. 35 
Furthermore, it was debated whether testing in rabbits may be waived in certain 36 
circumstances [5–9]. Initial reviews on rabbit embryo-fetal development (EFD) toxicity 37 
studies versus EFD studies in rat, however, suggested that the overall predictive capacity 38 
increases if developmental toxicity is tested in two mammalian species, i.e. in rat and rabbits 39 
[10–14]. Only recently the role of toxicokinetic for species-specific sensitivity differences in 40 
developmental toxicity of rats and rabbits has been considered [8, 15, 16]. Comparison of rat 41 
and rabbit embryo-fetal developmental toxicity data based on maternal systemic doses (AUC 42 
or Cmax) suggested that overall both species are equally sensitive [15]. However, for 43 
approximately 20 % of the compounds either the rat or the rabbit was found to be more than 44 
10fold sensitive (the 10fold threshold was based on differences between studies that tested 45 
the same compound). Hence, despite the overall concordance, testing in two species may 46 
still be relevant to capture potential hazards for consumers and patients. Understanding the 47 
reasons for species sensitivity may help to develop alternative testing strategies, based on in 48 
vitro tests, testing of non-protected vertebrate embryonic stages and/or computational 49 
predictions. For the development of chemicals such as pharmaceuticals, screening 50 
strategies to identify developmental toxicity are typically implemented in an early phase of 51 
product development. The potential of in vitro, ex vivo and non-mammalian in vivo assays is 52 
already considered in the new revision of the ICH S5 (R2) guideline for regulatory purposes 53 
under limited circumstances although these circumstances are yet to be defined [17].  54 
The retrospective analyses of Theunissen et al. [8, 15, 16] was based on a rather large set 55 
of compounds (379) and clearly indicated that part of the species differences can be 56 
attributed to toxicokinetics differences. While they provided a detailed dataset combining 57 
external doses, systemic concentrations and details on the type of effect, it was based on a 58 
coded dataset that did not reveal the identity of the compounds showing species differences. 59 
However, understanding the mechanistic basis of species differences, development of 60 
alternative testing approaches and independent validation of the findings by other groups 61 
would benefit from a set of known reference compounds. Therefore, we set out to validate 62 
the findings of Theunissen et al. [8, 15, 16] by repeating the analysis based on a larger set of 63 
non-confidential compounds with available rat and rabbit developmental toxicity data.  64 
 65 
1. Material and methods 66 
1.1. Data Collection 67 
Data were collected for compounds which have been tested in both rat and rabbit embryo-68 
fetal studies (EFD, segment II teratology studies or OECD 414). Compounds showing no 69 
developmental toxic effects in both species were not included in the database.  70 
Potential data were identified from various sources. (1) Previous reviews on developmental 71 
toxicity studies [5,6,11,18,19], comparing mainly pesticides, veterinary drugs and industrial 72 
chemicals were analysed. The data were then retrieved from the original data sources, i.e. 73 
peer-reviewed international documents (Table 1). When no or insufficient data for a specific 74 
substance were found in those sources, we searched the open literature to retrieve 75 
additional data (PubMed). (2) For pharmaceuticals, a list of all drugs in DrugBank [20] was 76 
extracted (August, 2015) and developmental toxicity data were collected using original peer-77 
reviewed, publicly available reports and material safety data sheets (Table 1). (3) Studies 78 
were also compiled from PharmaPendium® database (See supporting information, figure 1 79 
for details on obtaining data from the PharmaPendium database ( trademark of Reed 80 
Elsevier Properties SA, used under license)) [21]. Verification of the data was conducted for 81 
48.8 % of the compounds for which the original study was available. Around 20% of the 82 
populated data was based on limited information on Material Safety Data Sheets. 83 
The following parameters were entered in the database: range of doses tested as mg/kg 84 
b.w. per day, route of administration, developmental lowest effect level (dLOEL), 85 
developmental non-observed effect level (dNOEL), maternal lowest effect level (mLOEL), 86 
and developmental effects observed in the fetus at the dLOEL. These data were retrieved 87 
from the original study if available and all manifestations of developmental toxicity were 88 
taken into account (like embryofetal death, altered growth and structural changes or 89 
abnormalities). The rationale given by Janer et al. [5] was followed: (i) A final reason for 90 
considering both teratogenic and other developmentally toxic effects in combination is that 91 
the differences in the type of effects observed might not lead to different regulatory decisions 92 
in most regulatory frameworks (exceptions are e.g., pharmaceuticals). (ii) Developmental 93 
toxicity responses observed in different studies for the same substance are not always of the 94 
same type even when examined in the same species. In addition, toxicokinetic data 95 
reflecting maternal plasma concentrations (Cmax and AUC) at the dLOEL were included if 96 
available. In case that kinetic data were not available for the dLOEL, we attempted to identify 97 
kinetic information from different doses of other studies (females only), and linearly 98 
extrapolated the data to the dLOEL (toxicokinetic data was extrapolated from different 99 
studies for 9 compounds). If more than one study was available for the same chemical, 100 
species and route, the lowest dLOEL was taken. Also, the same route of exposure was 101 
compared between rat and rabbits to avoid possible differences based on route-specific 102 
pharmacokinetics. Data were considered only if the following quality criteria were fulfilled. (i) 103 
Exposure of animals was conducted from implantation to the end of gestation as described 104 
for the OECD TG 414. In some cases of data obtained from Safety Data Sheets the 105 
exposure period was not indicated. In this case we assumed that the appropriate exposure 106 
period was used if data were labelled as embryo fetal developmental effects, (ii) for the 107 
conclusion of a species sensitivity difference it was required that both LOEC and NOEC data 108 
were available from the less sensitive species. No other quality criteria have been applied. 109 
1.2. Data analysis 110 
Comparison of rat versus rabbit developmental toxic exposures was, if available, based on 111 
the maternal systemic doses at the dLOEL (AUC or Cmax) as differences between species 112 
are largely related to compound kinetics [15]. For those compounds without toxicokinetic 113 
data, the dLOEL was scaled by a correction for allometry on the basis of the body surface 114 
area to obtain the human-equivalent dose (HED). The HED in mg/kg for the rat and rabbit 115 
data was calculated by multiplying the effect concentrations by 0.16 and 0.32, respectively 116 
[22]. In agreement with Theunissen et al. [8], a factor of 10 related to overall study variations 117 
was selected as threshold to identify potential species-specific developmental toxicants. A 118 
factor of 10 is somewhat arbitrary but useful to describe the degree of sensitivity differences 119 
for the following reasons: (i) assuming that on average the species sensitivity difference is 120 
weak, a descriptive analysis of data with LOEC indicates that 25 % of the data are 121 
characterized by a higher difference between species (Fig. 2). This group of compounds 122 
exhibits a difference of more than 10. (ii) The factor of 10 has been used in previous studies 123 
and allows a better comparison to previous approaches. 124 
The comparison of rat versus rabbit developmental toxicity requires also consideration of 125 
maternal toxicity. For some compounds the maternal and developmental effects occurred at 126 
similar levels (dLOEL greater or equal to mLOEL). In these cases developmental effects 127 
may be secondary to maternal toxicity, though not demonstrated, and represent a 128 
confounding factor in the assessment of interspecies differences in developmental toxicity.  129 
Hence, the mLOELs were taken into account for the comparison between rat and rabbit 130 
specific developmental toxicants. A compound was considered as a selective developmental 131 
toxicant if it was observed at lower levels than the mLOEL or when no maternal toxicity was 132 
observed. If no maternal toxicity was reported for a given EFD study it was assumed that no 133 
maternal toxicity had occurred. Figure 1 shows how the comparison of the dLOELs between 134 
rat and rabbit was used to distribute the compounds in different classes with respect to their 135 
species-specificity. The entire database is available from a supplementary file and contains 136 
the collected compounds distributed in the different classes. 137 
Species sensitivity was also analysed in relation to the chemical’s mode of action (MoA). 138 
Five groups that include a minimum of seven compounds were identified and analysed from 139 
the entire database. The MoA was in relation to the main pharmacological mechanism (on-140 
target activity) or to its side-effects (e.g. antibiotics, off-target activity on microflora of 141 
rabbits). In order to determine whether rat and rabbit exhibit different relative sensitivity 142 
within a class of compounds, the cumulative distribution of the developmental LOELs (based 143 
on conversion of the effect dose to HED) were plotted separately for each species and mode 144 
of action. The median of the distributions were compared to determine if rat or rabbit display 145 
developmental specific toxicity to a group of compounds. The distributions were fitted using 146 
R software [23–25] with the “fitdistrplus” and “ggplot2” package.  The curve fitting model was 147 
selected based on the Akaike Information Criterion (AIC) indicating the best fit. 148 
2. Results 149 
From the three different data sources described in material and methods, 120 compounds 150 
were identified from previous reviews on developmental toxicity studies [5, 6, 18, 19]. The 151 
compounds comprised veterinary drugs [11], pesticides [6], industrial chemicals [5, 18] and 152 
some pharmaceuticals [19]. Analysis of the list of compounds obtained through DrugBank 153 
and other sources (table 1) resulted in the identification of 216 compounds, mainly 154 
pharmaceuticals. Additional 30 pharmaceuticals were identified from the PharmaPendium 155 
database. In total, 366 LOELs pairs for rat and rabbit were found representing 363 156 
compounds based on their CAS registry number. Most of the compounds entered were 157 
drugs (75%), followed by pesticides (19.7%), veterinary drugs (4%) and industrial chemicals 158 
(1.6%). The main route of exposure was oral (74%), followed by intravenous (7.6%), 159 
subcutaneous (5%) and topical administration (1.3%). Thirty-six compounds for which the 160 
route of exposure was not indicated were excluded from the analysis. The same route of 161 
exposure was compared between studies to avoid differences in internal concentrations (that 162 
may result in different dLOELs) due to different application routes.  163 
Figure 2 shows the comparison of the dLOELs between rat and rabbit, based on AUC/Cmax 164 
or HED in order to account for potential pharmacokinetic differences and species size-165 
dependent effects. For most of the compounds (n= 250, 76% of compounds with a dLOEL in 166 
one or both species), rat and rabbit showed a similar sensitivity with respect to 167 
developmental toxicity. For 37 compounds (11%) the rat study appeared more sensitive than 168 
the rabbit and in 43 compounds (13%) the rabbit study was more sensitive. Similar results 169 
were obtained if maternal toxic compounds were not considered (mLOEL≤dLOEL, see 170 
supplementary figure 2). In order to identify potential reasons for the difference between rat 171 
and rabbit, the mLOELs were included in the analysis and compounds were distributed into 172 
different classes according to the difference between dLOEL and maternal toxicity (Fig. 1).  173 
Table 2 shows the distribution of compounds within these different classes and all the data 174 
collected within the different classes is provided in a supplementary file. Class 1 represented 175 
species-specific developmental toxic compounds, with no developmental effects in one 176 
species or compounds for which HED or exposure-based dLOEL between rat and rabbits 177 
differ 10x or higher. A lack of concordance between rat and rabbit was observed for a total of 178 
33 compounds. The rabbit showed to be more sensitive than the rat for 11 compounds either 179 
because the rat study did not show developmental toxicity (N=2) or because the dLOEL was 180 
10x higher than the rabbit dLOEL (N=9). For 22 substances the rat was found to be more 181 
sensitive than the rabbit. For 5 compounds out of these 22, the rabbit study did not show any 182 
developmental effect. Class 2 included compounds that are developmental toxic in one 183 
species (at maternally non-toxic doses) but the other species showed maternal toxicity at 184 
similar doses. There were 17 compounds for which the rat showed to be more sensitive (no 185 
effects on rabbit or dLOEL fold change x10 or more) but maternal effects in the rabbit were 186 
observed in the range of developmental effects of the rat. Vice versa there were 11 187 
compounds for which the rat study did not establish a dLOEL or was 10fold higher but 188 
maternal effects were demonstrated. In class 3, compounds that show developmental effects 189 
in only one species with evidence to be caused by maternal toxicity were grouped (group of 190 
compounds for which relationships/causalities have been previously established). There 191 
were a total of 8 compounds for which the animal study reported that the effects observed 192 
have probably resulted indirectly from maternal effects (Class 3 list, supplementary file). In 193 
class 4, there were 78 compounds for which both species showed similar sensitivity for 194 
developmental toxicity (fold change in dLOEL < 10 based on HED or measured exposure 195 
data) with no maternal toxicity. There were 15 compounds for which data indicated that 196 
species differences of effect concentrations were related to differences in exposure (AUC, 197 
Cmax) probably due to differences in toxicokinetics between rat and rabbit (Table 3, 15 198 
compounds). These compounds were included in class 4. Data on internal exposure 199 
concentrations were, however, only available for 85 compounds out of the 366 entries (23 200 
%). Therefore, toxicokinetic differences may also account for the differences of other 201 
compounds distributed in class 1 given the lack of appropriate data. 202 
The remaining compounds could not be classified into any of the classes due to the lack of 203 
appropriate information. This inconclusive group was grouped as Class 5 comprising 183 204 
compounds. For 28 compounds from this class there was not enough data to draw a 205 
conclusion either because (1) the highest dose tested did not provoke developmental toxicity 206 
and maternal toxicity in one species and this dose was equal or less than 10x the dose 207 
inducing developmental toxicity in the other species or (2) no dNOEL was established in the 208 
less sensitive species (n=7) (when dLOEL differs 10x or more). Hence, an extension of the 209 
dose range may have indicated a similar dLOEL of both species. Information for each case 210 
is detailed in the supplementary file by appropriate comments for each compound. The 211 
remaining 155 compounds were classified inconclusive because developmental toxicity 212 
coincided with maternal toxicity and no causal evidence was found to conclude secondary 213 
developmental toxicity due to maternal toxicity. Providing of further data for these 214 
compounds may allow grouping them into one of the other five classes. 215 
2.1. Species sensitivity to certain MoAs 216 
Comparison of species sensitivity for certain MoAs (On-target or off-target) may indicate 217 
mechanisms leading to species differences. However, only five groups that comprised a 48 218 
compounds (i.e. 15% of the compounds) could be identified (glucocorticoid agonists, COX 219 
inhibitors, tyrosin-kinase inhibitors, antibiotics and lanosterol 14 α-demethylase inhibitors). In 220 
order to demonstrate potential species differences a plot of cumulative distribution of the 221 
HED at LOELs for the different classes of compounds was used which indicates species-222 
differences more pronounced (Fig. 3, for corresponding scatter plots see supporting 223 
information, figure 3). The MoA-specific analysis did not indicate species-specific differences 224 
for tyrosine kinase inhibitors, COX inhibitors and glucocorticoid agonists but for lanosterol 14 225 
α-demethylase (rat 2.7x more sensitive) and antibiotics (rabbit 3.6x more sensitive). 226 
However, there was no statistical difference based on the comparison of median of the 227 
distributions (data not shown). It should be noted that the analysis did not include 228 
compounds for which no dLOEL was established (3 lanosterol 14 α-demethylase inhibitors in 229 
rabbit, 1 antibiotic in the rabbit, 5 antibiotics in the rat and 1 COX-inhibitor and glucocorticoid 230 
agonist each in the rat, supporting information figure 3).  231 
 232 
3. Discussion 233 
In this study the analysis of developmental toxicity data – if compared to previous reviews - 234 
has resulted in a comparatively high number of non-confidential compounds (N= 363, mostly 235 
pharmaceuticals) for which rat and rabbit developmental toxicity data were available [5, 11, 236 
18, 19]. The compound overlap with existing studies [15] is approximately 20 % 237 
(Theunissen, personal communication; based on 177 out of 379 compounds for which the 238 
identity was known to the main author). The interpretation of the established data set is 239 
partially difficult due to variations in experimental designs, strain of animal used, methods in 240 
analysis of foetuses and interpretation of the data. Hence, for some compounds conclusions 241 
with respect to species sensitivity differences could be confounded. It should be mentioned 242 
that the database included only a few number of industrial chemicals. Potentially the list 243 
could be extended by reviewing individual publications or the IUCLID files provided by 244 
ECHA.  245 
Previous large-scale comparative study on rat and rabbit developmental toxicity [8, 15, 16] 246 
revealed an overall similar sensitivity of the rat and rabbit (80% of all compounds). However, 247 
the studies did not reveal the identity of the compounds and information on MoA was only 248 
available for a limited number of compounds (135 out of 379). In contrast, our study was 249 
based on non-confidential data and information on the MoA was available for all the 250 
compounds allowing the comparison of rat and rabbit developmental toxicity on specific 251 
mode of actions. Internal exposure data were only available for 85 out of the 366 252 
compounds. Hence, it cannot be excluded that in some cases differences in the systemic 253 
doses have caused the species differences. Therefore, for those compounds without internal 254 
exposure data the comparison of rat and rabbit developmental exposures was based on the 255 
human equivalent dose. In agreement with Theunissen et al. [15] we found that most of the 256 
compounds showed similar sensitivity between rat and rabbit (76%) and around 24% of the 257 
compounds revealed an increased sensitivity for rat (37 out of 330) or rabbit (43 out of 330). 258 
3.2. Role of maternal toxicity in interspecies comparison      259 
Interpretation of developmental toxicity can be difficult due to the indirect role of maternal 260 
toxicity [26]. Disturbances of maternal homeostasis or physiology (due to chemical 261 
exposure) may affect normal development of the embryo. The effect would be secondary to 262 
maternal toxicity and not a direct effect of the chemical over the embryo caused by direct 263 
interference of the compound with important differentiation processes. A common example 264 
found in the literature is indacrinone that produces maternal hypokalemia as the principal 265 
cause of the fetal skeletal defects observed in rats [27]. In our study, we identified two 266 
classes of substances for which maternal toxicity could have an impact on species 267 
differences. First, we identified compounds that show developmental toxicity in one species 268 
(at maternally non-toxic doses) but the other species shows maternal toxicity at similar 269 
doses. In this case developmental toxicity could be masked by a differential sensitivity for 270 
maternal toxicity (Class 2 list supplementary file). Second, we identified a set of compounds 271 
in which developmental effects were only observed in one species and were secondary to 272 
the maternal toxicity observed (Class 3 list supplementary file, it includes 8 compounds: 4 273 
antibiotics, 2 renin-angiotensin inhibitors, 1 colony stimulating factor and 1 dopamine 274 
agonist). These differences could also reflect a species-specific maternal sensitivity related 275 
to a certain mode of action. For instance, many compounds in Class 3 are antibiotics (e.g. 276 
norfloxacin). It is well known that rabbits are not a suitable species to test developmental 277 
toxicity of antibiotics because of their gastrointestinal intolerance due to the dependency on 278 
microbial activity for digestion [28]. Increased susceptibility of the rabbit was also reported 279 
for the group of renin-angiotensin inhibitors [29] (e.g. telmisartan). The adult rabbit is 280 
particularly sensitive to renin-angiotensin inhibitors, showing a greater antihypertensive 281 
effect than does the rat. Placental blood flow and oxygen delivery decrease in relation to 282 
blood pressure and fetal toxicity may result from this decrease in oxygen delivery [30]. 283 
Rabbit-specific developmental toxicity potentially caused indirectly by maternal toxicity was 284 
also observed for granulocyte colony-stimulating factors (G-CSF), such as filgrastim. The 285 
developmental toxicity of these compounds could be related to an exaggerated 286 
pharmacodynamic effect specific for rabbits [31].  Neutrophils increase markedly due to G-287 
CSF administration in rabbit causing ischemia of the placenta vessels and consequently fetal 288 
mortality [32]. Class 3 compounds with only developmental toxicity in the rat include 289 
dopamine agonists (pramipexole), of which the effects are thought to be secondary to 290 
reduction of prolactin levels caused by the drug. Prolactin is required for implantation and 291 
pregnancy maintenance in rats but not in rabbits or humans [33]. It can be concluded that 292 
the compounds grouped in class 3 in this study (Supplementary file) are likely to be non-293 
developmental or non-teratogenic toxic compounds. Inclusion of compounds showing 294 
developmental toxicity as a consequence of maternal influences into a list of model 295 
compounds would be of particular concern for the establishment of alternative prediction 296 
models. These models may not indicate developmental toxicity resulting from maternal 297 
toxicity. 298 
Compounds for which it could not be concluded whether the developmental toxicity was 299 
secondary to maternal toxicity (inconclusive compounds, representing about 47% of rat-300 
rabbit comparisons) may principally represent a source of further species-specific 301 
developmental toxic compounds provided that further data would confirm that species 302 
differences is not based on internal exposure differences and/or maternal toxicity. Many 303 
reviews/discussions have been published regarding the relationship between maternal 304 
toxicity and embryo-fetal toxicity with differing conclusions [29, 34-38]. Therefore findings 305 
should be handled on a case by case basis to establish a causal relationship. The 306 
determination of whether or not the relationship is casual is difficult to make and needs a 307 
comprehensive assessment of the data coupled with expert judgement. 308 
3.2. Role of kinetics/metabolism in interspecies comparison 309 
The key processes that control embryonic development are regulated by a limited number of 310 
signalling pathways that are evolutionary conserved over a broad range of species [39]. This 311 
suggests that discordance in developmental toxicity testing could often be due to factors not 312 
related to the target availability or affinity. For instance, differential pharmacokinetics could 313 
have a strong impact on internal bioavailable amount of a compound reaching the embryonic 314 
target. In our analysis we found 6 compounds: fingolimod, voriconazole, cabozantinib, 315 
alitretinoin, mirabegron and entecavir (Table 3), in which differences of internal exposure 316 
concentrations and toxicokinetics may have been involved in the observed species-specific 317 
differences in developmental responses. Also, there were 9 compounds that showed a 318 
similar sensitivity between rat and rabbit after to the HED conversion. An example is the 319 
group of retinoid compounds, for which differences in kinetics among species might play a 320 
major role in the different potency rankings in developmental toxic responses between 321 
species [40]. This example shows that the knowledge of kinetic processes (absorption, 322 
distribution, metabolism and excretion – ADME –) is critical when interpreting the lack of 323 
concordance between species in developmental toxicity studies [15, 16, 41]. The HED 324 
approach can at least cover systematic species differences provoked by size differences, 325 
hence, reducing the number of false positives. However, some drugs are not amenable to 326 
simple allometric scaling, i.e. drugs that are highly protein-bound, that undergo extensive 327 
metabolism or active transport, significant biliary transport or drugs whose targets are 328 
subject to interspecies differences in expression, affinity and distribution [42]. An example of 329 
interspecies difference in target affinity is the pesticide flumioxazin (class 1 rat, table 5), a 330 
protoporphyrinogen oxidase (PPO) inhibitor. Studies have been shown that protoporphyrin 331 
IX accumulation corresponded to the developmental toxicity displayed by flumioxazin and 332 
that the rabbit show no accumulation, suggesting a link between PPO inhibition and 333 
developmental effects [43].     334 
The maternal metabolism can vary widely between species and could also represent a factor 335 
for interspecies discordance. The most important drug-metabolising enzyme family is 336 
cytochrome P450 (CYP) and differences in CYP isoforms between species are a major 337 
cause for differences in species drug metabolism [44]. For instance, similarities can be found 338 
for CYP2E1, which is conserved among species and shows no appreciable differences with 339 
respect to expression and catalytic activity. CYP1A is also conserved among species, but 340 
some catalytic differences have been observed. In contrast, CYP2C, -2D and -3A show 341 
substantial species differences in terms of isoform, expression, organ-specificity and 342 
catalytic activity [44]. These differences are more important if the resulting metabolites have 343 
pharmacological or toxicological impact. A clear example found in the literature is the 344 
discordance response to ethylene glycol (EG) exposure between rat and rabbit. This is due 345 
to differences in rates of hepatic metabolism of EG to the toxic metabolite glycolic acid and 346 
limited transfer in the rabbit embryo relative to the rat [28]. In our study, additional details on 347 
metabolism that could explain species differences to compounds showing increased 348 
developmental toxicity are compiled in supplementary file. Much effort should be devoted to 349 
profile metabolic pathways, especially in the rabbit, in order to understand differences 350 
among species and improve predictivity for the human situation.  351 
3.3. On-target/off-target effect based comparison 352 
Only a subset of compounds (10 %) showed increased sensitivity of the developing fetus in 353 
one species not related to maternal toxicity (Class 1, table 4 and table 5) being selective 354 
developmental toxicants for the rat or rabbit. Given the higher number of available data a 355 
comparison with regard to the relation of on-target or off-target effects, cumulative species 356 
sensitivity was conducted for five groups of compounds (Figure 3). The results reflected the 357 
known species-specific sensitivity of rabbit to antibiotics. The reason for the higher sensitivity 358 
of rats to lanosterol 14 α-demethylase inhibitors is not known and due to the lack of data it is 359 
difficult to conclude if there are e.g. potential target sensitivity differences. In contrast, rat 360 
and rabbit did not show any differential sensitivity to COX-inhibitors, tyrosine kinase 361 
inhibitors or glucocorticoid agonists, even though it is been previously reported that rabbits 362 
are particularly sensitive to the teratogenic property of glucocorticoids leading to high 363 
incidences of cleft palate [45]. This information on overall species differences for groups of 364 
compounds could be useful to predict the relative responses of these species to previously 365 
untested compounds in such groups.  366 
4. Conclusions 367 
The study confirmed the overall similar sensitivity of developmental toxicity in rat and rabbits 368 
based on a non-confidential dataset and that a limited number of compounds exhibit a 369 
>10fold difference between rabbits and rats. A set of potential reference compounds that 370 
could be used to study the mechanistic basis of species differences or to develop alternative 371 
testing approaches that may capture differences between rat and rabbit was provided. 372 
Some factors were identified that might be confounding in the assessment of interspecies 373 
differences in developmental toxicity, such as the interference of maternal toxicity and 374 
differences in pharmacokinetics. Understanding of these confounding factors would be 375 
valuable to understand in more detail what drives interspecies differences.  376 
The list of reference compounds could be used to evaluate the potential of in vitro 377 
approaches, the culture of whole embryos of rodents and lower vertebrates (e.g. Xenopus 378 
and zebrafish) [46–48] computational or read across approaches [7, 49–51], or a 379 
combination of these to predict (human) developmental toxicity. Since human developmental 380 
toxicity data are limited to anecdotal, accidental or unintended adverse effects, in vivo animal 381 
results are at present considered as the reference for the screening and regulatory 382 
development of chemicals for human use. This lack of comparative human data has also 383 
driven the multiple test species approach, to capture the uncertainty and potential limited 384 
concordance between one of the test species with humans – albeit this may increase the 385 
number of false positives. Alternative testing approaches like in the lower vertebrate need to 386 
be validated as predictive for the in vivo animal models used later in the regulatory part of 387 
the development. Hence, the testing in a second species may not be waived until it is 388 
demonstrated that other approaches would reveal the same level of information on potential 389 
developmental toxicity. Albeit the number of reference compounds is at present limiting, 390 
future revisions of the data analysis would increase the basis. Industry and regulators could 391 
greatly support any effort to establish alternative testing strategies if confidential data would 392 
at least be made available to the scientific community. 393 
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 649 
Fig. 1. Flow chart of the classification approach followed to compare the dLOELs between rat and rabbit. See supporting file, table 1 650 
for the detailed description of the process. 651 
 652 
Fig. 2. Range of sensitivity for developmental LOEL in rats and rabbits (n=330). Compounds, for 653 
which no dLOEL was reached in the rat or rabbit (n=51 for the rabbit and n=52 for the rat), the 654 
maximum concentration was used for rat and rabbit sensitivity comparison. The values were 655 
sorted with values>0 indicating a stronger susceptibility of rabbits compared to rat. Differences 656 
of the dLOEL (based on the AUC/Cmax or HED conversion) within 10fold between rat and 657 
rabbit were considered as similar sensitive. 658 
 Number of 
substances 
Species Rat Rabbit Total 
Class 1. One species is more sensitive than the other  
Fold change in developmental effect level ≥ 10 










Class 2. Developmental toxicity in one species but maternal effects observed for the 
other species 
17 11 28 
Class 3. One species is more sensitive, but developmental effects are secondary to 
maternal toxic effects 
1 7 8 
Class 4. Compounds with similar sensitivity between rat and rabbit 
Similar sensitivity due to maternal plasma concentrations 





Class 5. Inconclusive compounds 
Maternal toxicity involved  






Table 2. Distribution of the compounds analyzed among the different classes (N=330). * Studies 660 
where the higher dose tested without developmental and maternal effects in one species was 661 
10x lower than the dose inducing developmental effects in the other species or studies where 662 
dLOEL differs 10x or more but no NOAEL was reached for the less sensitive species. 663 
Comparisons were based on HED or maternal plasma concentrations if available.  664 
 665 
 666 




Fold change dLOEL 
maternal systemic 
dose or *HED Reference 
  Rabbit/Rat Rabbit/Rat 
 
Fingolimod hydrochloride 162359-56-0 15.0 0.5 [52] 
Voriconazole 137234-62-9 10.0 4.9 [53] 
Cabozantinib (S)-maleate 1140909-48-3 10.0 0.6 [54] 
    
 
  
Rat/Rabbit Rat/Rabbit  
Alitretinoin (9Cis-retinoic acid) 5300-03-8 10.0 1.5 [55] 
Mirabegron 223673-61-8 10.0 1.5 [56] 
Entecavira 142217-69-4 20.0 2.3 [57] 
Triclabendazole 68786-66-3 10 5* [58] 
Nicardipine Hydrochloride 199119-58-9 10 5* [59] 
Lamivudine 54527-84-3 10 5.0* [60] 
Trifloxysulfuron-Sodium 134678-17-4 15 7.5* [61] 
Beclometasone Dipropionate 5534-09-8 10 5* [45] 
Fluazinam 79622-59-6 12.5 6.25* [61] 
Raloxifene Hydrochloride 82640-04-8 10 5.00* [62] 
Butralin 33629-47-9 11.1 5.6* [61] 
Naratriptan Hydrochloride 121679-13-8 10 5* [63] 
 667 
Table 3. List of compounds for which rat or rabbit showed differences related to absorption 668 
and/or kinetics. Apparent specific developmental toxicity (fold change dLOEL external dose 669 
between species > 10) but maternal systemic data or HED conversion indicated that species 670 
differences are likely related to differences in absorption and/or dose kinetics between rat and 671 






   Rabbit (mg/kg/day) Rat (mg/kg/day) Route of 
exposure 
Reference 
Compounds CasNR Pharmacological MoA dLOEL mLOEL dNOAEL dLOEL mLOEL dNOAEL 
Pharmaceuticals           
Eletriptan 143322-58-1 
Selective 5-hydroxytryptamine 1B/1D 
receptor agonist 
5 >50 <5 100 100 30 po [64] 
Finafloxacin 209342-40-5 Fluoroquinolone antibiotic1 1 >9 <1 100 500 30 po [65] 
Gabapentin 60142-96-3 Gabamimetic agent 60 1500 <60 1500 >1500 300 po [66] 
Latanoprost 130209-82-4 Selective FP receptor PGF2α agonist 0.005 >0.3 0.001 >0.25 >0.25 ≥0.25 iv [67] 
Linagliptin 668270-12-0 
Competitive and reversible DPP-4 enzyme 
inhibitor 
4 150 <4 240 240 30 po [68] 
Oxaprozin 21256-18-8 Selective cyclo-oxygenase inhibitor 7.5 N/A <7.5 500 N/A 200 po [69] 
Propafenone  34183-22-7 Sodium channel blocker 15 150 <15 600 600 270 po [70] 
Tafluprost 209860-87-7 Selective FP receptor PGF2α agonist 0.00003 >0.0003 <0.00003 0.01 >0.030 0.003 iv [71] 
Pesticides           
Isoxaflutole 141112-29-0 HPPD inhibitors2 5 100 <5 100 500 10 po [61] 
Veterinary drugs           
Fenbendazole 43210-67-9 Tubulin binding 63 >63 25 >2500 >2500 ≥2500 po [72] 
Firocoxib* 189954-96-9 Selective cyclo-oxygenase inhibitor 3 10 1 300 >1000 3 po [73] 
 678 
Table 4. List of compounds for which the rabbit study showed to be more sensitive than the rat study (no effects in rat study were observed or 679 
fold change dLOEL was ≥ 10, based on maternal plasma concentrations (for linagliptin and finafloxacin) or HED (rest of compounds). The route 680 
of exposure is the same for rat and rabbit: po= oral, sc=subcutaneous, iv= intravenous.  681 
1No target in mammals, 2Target for plants. Abbreviations: FP, fluoroprostaglandin; DPP, dipeptidyl peptidase; HPPD, 4-Hydroxyphenylpyruvate 682 
dioxygenase. *Rat and rabbit showed no difference for the NOEL (fold change <10) for this compound, differences for the LOEL may have just 683 
been produced by selection of different concentrations for testing. 684 
 685 
  686 
      Rabbit (mg/kg/day) Rat (mg/kg/day)   




Drugs          
 
Artemether 71963-77-4 Complexation with heme  175 >175 105 10 >10 3 po [74] 
Bicalutamide 90357-06-5 Androgen receptor antagonist >200 200 ≥200 10 >10 1 po [75] 
Cariprazine  1083076-69-0 D2 and D3 partial agonist >5 5 ≥5 0.5 2.5 <0.5 po [76] 
Caspofungin Acetate 179463-17-3 1,3-beta-glucan synthase inhibitor1 3 6 1 0.5 >5 >0.5 iv [77] 
Clomifene Citrate 7619-53-6 
Selective estrogen receptor modulator 
(SERM) 
20 N/A 8 1 40 <1 Po [78] 
Irinotecan  100286-90-6 DNA topoisomerase I inhibitor 6 N/A 0.24 1.2 N/A 0.06 Iv [79,80] 
Loxapine 1977-10-2 
Dopamine antagonist and serotonin 5-HT2 
blocker 
>10 N/A N/A 1 N/A N/A po [81] 
Miltefosine 58066-85-6 
Inhibits cytochrome-c oxidase and protein 
kinase B 
6 > 2.4 2.4 1.2 >2.4 0.6 po [82] 
           
Nilotinib 641571-10-0 Tyrosine kinase inhibitor 300 300 100 30 100 10 po [83] 
Olopatadine  140462-76-6  Histamine H1 antagonist 400 >400 100 60 600 >60 po [84] 
Ospemifene 128607-22-7 
Selective estrogen receptor modulator 
(SERM) 
>30 10 ≥30 0.1 1 <0.1 po [85] 
Tiotropium bromide 186691-13-4 Muscarinic receptor antagonist 0.05 >0.05 0.011 0.007 >0.139 7.50E-04 inh [86] 
Pesticides           
Atrazine 1912-24-9 Photosynthesis II inhibitor2 75 75 5 5 25 <5 po [61] 
Diniconazole 83657-24-3 
Lanosterol 14 alpha-demethylase (Cyp51) 
inhibition1 
>30 >30 ≥30 1 20 <1 po [61] 
Fluazifop-P-Butyl 79241-46-6 ACCase Inhibitor2 50 50 10 5 300 1 po [61] 
Flumioxazin 103361-09-7 
Protoporphyrinogen Oxidase (PPG oxidase 
or Protox) Inhibitor2 
>3000 3000 ≥3000 10 30 3 po [61] 
Flusilazole 85509-19-9 
Lanosterol 14 alpha-demethylase (Cyp51) 
inhibition1 
35 35 12 0.4 50 0.2 po [61] 
Hexaconazole 79983-71-4 
Lanosterol 14 alpha-demethylase (Cyp51) 
inhibition1 
50 100 25 2.5 250 <2.5 po [61] 
Molinate 2212-67-1 Inhibition of lipid synthesis2 200 200 20 35 140 2.2 po [61]
 
Sulfentrazone 122836-35-5 
Protoporphyrinogen Oxidase (PPG oxidase 
or Protox) Inhibitor2 
250 250 100 25 50 10 po [61] 
Tralkoxydim 87820-88-0 ACCase Inhibitor2 100 100 20 3 200 1 po [61] 
Triadimenol 55219-65-3 
Lanosterol 14 alpha-demethylase (Cyp51) 
inhibition1 
>125 125 ≥125 5 15 <5 po [61] 
Table 5. List of compounds classified in class 1 for which the rat study showed to be more sensitive than the rabbit study (no effects in rabbit 687 
study were observed or fold change dLOEL ≥ 10, based on maternal plasma concentrations (for cariprazine, nintedanib and ospemifene) or HED 688 
(rest of compounds). Route of exposure is the same for rat and rabbit as indicated: po= oral, top= topical. 1Target for fungi, 2Target for plants. 689 















Fig. 3. Relative species sensitivity to specific chemical classes with the same mode of action (on-target activity) or off-target effects (antibiotics 705 
and lanosterol 14-alpha demethylase inhibitors). Cumulative distribution for compounds grouped into five different classes. (Data points are 706 
percentiles for the rat    and rabbit   707 
